Yunyun Luo1,2, Jonathan Samuels3, Svetlana Krasnokutsky3, Inger Byrjalsen4, Virginia B Kraus5,6, Yi He1, Morten A Karsdal1, Steven B Abramson3, Mukundan Attur3, Anne C Bay-Jensen7. 1. Rheumatology, Biomarkers and Research, Nordic Bioscience, Herlev Hovedgade 207, 2730, Herlev, Denmark. 2. Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 3. Division of Rheumatology, NYU School of Medicine and NYU Langone Orthopaedic Hospital, New York, USA. 4. Clinical Development, Nordic Bioscience, Herlev, Denmark. 5. Division of Rheumatology, Department of Medicine, Duke University School of Medicine, Durham, USA. 6. Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, USA. 7. Rheumatology, Biomarkers and Research, Nordic Bioscience, Herlev Hovedgade 207, 2730, Herlev, Denmark. acbj@nordicbio.com.
Abstract
BACKGROUND: Osteoarthritis (OA) is a disease with multiple endotypes. A hallmark of OA is loss of cartilage; however, it is evident that the rate of cartilage loss differs among patients, which may partly be attributed to differential capacity for cartilage repair. We hypothesize that a low cartilage repair endotype exists and that such endotypes are more likely to progress radiographically. The aim of this study is to examine the associations of level of cartilage formation with OA severity and radiographic OA progression. We used the blood-based marker PRO-C2, reflecting type II collagen formation, to assess levels of cartilage formation. MATERIALS AND METHODS: The type II collagen propeptide PRO-C2 was measured in the serum/plasma of knee OA subjects from New York University (NYU, n = 106) and a subcohort of the phase III oral salmon calcitonin (sCT) trial SMC021-2301 (SMC, n = 147). Risk of radiographic medial joint space narrowing (JSN) over 24 months was compared between quartiles (very low, low, moderate, and high) of PRO-C2. Associations were adjusted for age, gender, BMI, race, baseline pain levels, and baseline joint space width. RESULTS: In both the NYU and SMC cohorts, subjects with low PRO-C2 levels had greater JSN compared with subjects with high PRO-C2. Mean difference in JSN between subjects with very low and high levels of PRO-C2 was 0.65 mm (p = 0.002), corresponding to a 3.4 (1.4-8.6)-fold higher risk of progression. There was no significant effect of sCT treatment, compared with placebo, on JSN over 2 years before stratification based on baseline PRO-C2. However, there were proportionately fewer progressors in the sCT arm of the very low/low PRO-C2 group compared with the moderate/high group (Chi squared = 6.5, p = 0.011). CONCLUSION:Serum/plasma level of type II collagen formation, PRO-C2, may be an objective indicator of a low cartilage repair endotype, displaying radiographic progression and superior response to a proanabolic drug. LEVEL OF EVIDENCE: Level III post hoc exploratory analysis of one longitudinal cohort and a sub-study from one phase III clinical trial.
RCT Entities:
BACKGROUND:Osteoarthritis (OA) is a disease with multiple endotypes. A hallmark of OA is loss of cartilage; however, it is evident that the rate of cartilage loss differs among patients, which may partly be attributed to differential capacity for cartilage repair. We hypothesize that a low cartilage repair endotype exists and that such endotypes are more likely to progress radiographically. The aim of this study is to examine the associations of level of cartilage formation with OA severity and radiographic OA progression. We used the blood-based marker PRO-C2, reflecting type II collagen formation, to assess levels of cartilage formation. MATERIALS AND METHODS: The type II collagen propeptidePRO-C2 was measured in the serum/plasma of knee OA subjects from New York University (NYU, n = 106) and a subcohort of the phase III oral salmon calcitonin (sCT) trial SMC021-2301 (SMC, n = 147). Risk of radiographic medial joint space narrowing (JSN) over 24 months was compared between quartiles (very low, low, moderate, and high) of PRO-C2. Associations were adjusted for age, gender, BMI, race, baseline pain levels, and baseline joint space width. RESULTS: In both the NYU and SMC cohorts, subjects with low PRO-C2 levels had greater JSN compared with subjects with high PRO-C2. Mean difference in JSN between subjects with very low and high levels of PRO-C2 was 0.65 mm (p = 0.002), corresponding to a 3.4 (1.4-8.6)-fold higher risk of progression. There was no significant effect of sCT treatment, compared with placebo, on JSN over 2 years before stratification based on baseline PRO-C2. However, there were proportionately fewer progressors in the sCT arm of the very low/low PRO-C2 group compared with the moderate/high group (Chi squared = 6.5, p = 0.011). CONCLUSION: Serum/plasma level of type II collagen formation, PRO-C2, may be an objective indicator of a low cartilage repair endotype, displaying radiographic progression and superior response to a proanabolic drug. LEVEL OF EVIDENCE: Level III post hoc exploratory analysis of one longitudinal cohort and a sub-study from one phase III clinical trial.
Authors: M A Karsdal; M Michaelis; C Ladel; A S Siebuhr; A R Bihlet; J R Andersen; H Guehring; C Christiansen; A C Bay-Jensen; V B Kraus Journal: Osteoarthritis Cartilage Date: 2016-08-02 Impact factor: 6.576
Authors: Svetlana Krasnokutsky; Charles Oshinsky; Mukundan Attur; Sisi Ma; Hua Zhou; Fangfei Zheng; Meng Chen; Jyoti Patel; Jonathan Samuels; Virginia C Pike; Ravinder Regatte; Jenny Bencardino; Leon Rybak; Steven Abramson; Michael H Pillinger Journal: Arthritis Rheumatol Date: 2017-04-28 Impact factor: 10.995
Authors: Janet L Huebner; Anne C Bay-Jensen; Kim M Huffman; Yi He; Diana J Leeming; Gary E McDaniel; Morten A Karsdal; Virginia B Kraus Journal: Arthritis Rheumatol Date: 2014-09 Impact factor: 10.995
Authors: M van der Esch; J Knoop; M van der Leeden; L D Roorda; W F Lems; D L Knol; J Dekker Journal: Osteoarthritis Cartilage Date: 2015-01-14 Impact factor: 6.576
Authors: Virginia Byers Kraus; Jamie E Collins; H Cecil Charles; Carl F Pieper; Lawrence Whitley; Elena Losina; Michael Nevitt; Steve Hoffmann; Frank Roemer; Ali Guermazi; David J Hunter Journal: Arthritis Rheumatol Date: 2017-12-15 Impact factor: 10.995
Authors: Catherine Legrand; Usman Ahmed; Attia Anwar; Kashif Rajpoot; Sabah Pasha; Cécile Lambert; Rose K Davidson; Ian M Clark; Paul J Thornalley; Yves Henrotin; Naila Rabbani Journal: Arthritis Res Ther Date: 2018-06-22 Impact factor: 5.156
Authors: Ioanna Tachmazidou; Konstantinos Hatzikotoulas; Lorraine Southam; Jorge Esparza-Gordillo; Valeriia Haberland; Jie Zheng; Toby Johnson; Mine Koprulu; Eleni Zengini; Julia Steinberg; Jeremy M Wilkinson; Sahir Bhatnagar; Joshua D Hoffman; Natalie Buchan; Dániel Süveges; Laura Yerges-Armstrong; George Davey Smith; Tom R Gaunt; Robert A Scott; Linda C McCarthy; Eleftheria Zeggini Journal: Nat Genet Date: 2019-01-21 Impact factor: 38.330
Authors: Felix Eckstein; Jeffrey L Kraines; Aida Aydemir; Wolfgang Wirth; Susanne Maschek; Marc C Hochberg Journal: Ann Rheum Dis Date: 2020-02-25 Impact factor: 19.103
Authors: Anne C Bay-Jensen; Ali Mobasheri; Christian S Thudium; Virginia B Kraus; Morten A Karsdal Journal: Curr Opin Rheumatol Date: 2022-01-01 Impact factor: 5.006